Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística

Cantón, Rafael; Cobos, N.; Gracia, Javier de; Baquero, Fernando; Honorato, J.; Gartner, Sílvia; Álvarez, Antonio; Salcedo, Antonio; Oliver, Antonio; García-Quetglas, E.

doi:10.1016/s0300-2896(05)70731-6

Cited by 52 publications

(9 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cystic fibrosis, recurrent infection and obstruction of the airways lead to inflammation, lung damage in the long term, respiratory insufficiency, and death [ 36 ]. Given that inflammation is present from onset, anti-inflammatory drugs such as corticosteroids could prove useful for delaying impairment of lung function in the long term.…”

Section: Discussionmentioning

confidence: 99%

Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis

et al. 2014

View full text Add to dashboard Cite

BackgroundPulmonary exacerbation is one of the main risk factors for death in patients with cystic fibrosis. Several biomarkers have proven useful in the diagnosis and treatment of pulmonary exacerbations, although none has been associated with severity. The objective of the present study was to investigate whether C-reactive protein (CRP) level was associated with the severity of pulmonary exacerbation requiring admission to hospital in patients with cystic fibrosis.MethodsWe designed a severity index for exacerbations based on 4 clinical parameters and determined whether there was an association between CRP levels and severity of the exacerbation. We also investigated the association between CRP and baseline functional and clinical variables.ResultsTwenty-seven patients with cystic fibrosis required 62 admissions to hospital. CRP levels were not significantly associated with the severity index, although they were associated with specific patient characteristics: colonization by Pseudomonas aeruginosa, allergic bronchopulmonary aspergillosis, treatment with oral corticosteroids, and number of severe exacerbations treated with intravenous antibiotics during the previous year.ConclusionsCRP level is not associated with the severity of pulmonary exacerbations, but it is associated with specific clinical characteristics. This simple scoring system (severity index) could prove very useful for evaluating the severity of exacerbations.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…En pacientes con FQ, con primoinfección por PA, está demostrado el beneficio del tratamiento precoz con ATN 35 44 ), ya que se consiguen altas tasas de erradicación y se retrasa la infección bronquial crónica [35][36][37][38][39][40][41][42][43][44] .…”

Section: Antibióticos Nebulizados En Fibrosis Quísticaunclassified

“…La administración prolongada de ATN ha demostrado su eficacia en el tratamiento de la infección bronquial crónica por PA en pacientes con FQ 31,[35][36][37][38][39][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] . Las opciones son diversas [35][36][37][38] e incluyen la terapia antibiótica inhalada intermitente, con periodos de 28 días de tratamiento y 28 de descanso, con TIS 31,45-49 o AZLI 38,[55][56][57][58][59] , o el tratamiento continuo con colistina 36,39,[50][51][52] .…”

Section: Antibióticos Nebulizados En Fibrosis Quísticaunclassified

“…Las opciones son diversas [35][36][37][38] e incluyen la terapia antibiótica inhalada intermitente, con periodos de 28 días de tratamiento y 28 de descanso, con TIS 31,45-49 o AZLI 38,[55][56][57][58][59] , o el tratamiento continuo con colistina 36,39,[50][51][52] . Disponemos ya de estudios con otros ATN, aun no comercializados en España 32 , que han demostrado ser eficaces y bien tolerados en pacientes con FQ, como el levofloxacino 60,61 , la amikacina liposomal (Arikace ® ) 32,62 y la combinación de fosfomicina y tobramicina 63 .…”

Section: Antibióticos Nebulizados En Fibrosis Quísticaunclassified

See 1 more Smart Citation

Terapia nebulizada. Año SEPAR

Olveira

Muñoz

Domenech

2014

Archivos de Bronconeumología

View full text Add to dashboard Cite

“…8 Pseudomonas aeruginosa is a Gram-negative bacterium that represents one of the most isolated species from the respiratory tract in seriously hospitalized patients, causing infections with high mortality due to high resistance to antibiotics. 9,10 Staphylococcus aureus is a Gram-positive bacterium that causes a wide variety of infections, mainly infections in the bloodstream and food poisoning, its main impact is due to strains resistant to methicillin (MRSA). 11 Ceramic compounds are considered as third generation orthopedic biomaterials due to their ease of matching the chemical, biological and mechanical properties of bone.…”

Section: Introductionmentioning

confidence: 99%

Alumina-Hydroxyapatite-Silver Spheres With Antibacterial Activity

Silva-Holguín

Reyes-López

2021

Dose-Response

View full text Add to dashboard Cite

Researchers are currently looking for materials that are stable, functional, aesthetic, and biocompatible without infections. Therefore, there is a great interest in obtaining a material that has a balance between aesthetic, biological, mechanical, and functional factors, which can be used as an infection control material. The addition of hydroxyapatite to alumina make highly bioactive scaffolds with mechanical strength. Biomedical applications require antibacterial properties; therefore, this idea leads to great interest in the development of new synthetic routes of ceramic biomaterials that allow the release of nanoparticles or metal ions. This investigation presents the obtention of alumina-hydroxyapatite spheres doped with silver nanoparticles with antibacterial effect against various Gram-positive and negative bacteria related to drug-resistance infections. The microstructural and spectroscopic studies demonstrate that the spheres exhibit a homogeneous structure and crystal hydroxyapatite and silver nanoparticles are observed on the surface. The antimicrobial susceptibility was verified with the agar diffusion and turbidimetry methods in Gram-negative ( Escherichia coli and Pseudomonas aeruginosa) and Gram-positive ( Staphylococcus aureus and Bacillus subtilis) bacteria. All bacteria used were susceptible to the alumina-hydroxyapatite-silver spheres even at lower silver concentration. The composites have a higher possibility for medical applications focused on the control of drug-resistance microorganisms.

show abstract

Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística

Cited by 52 publications

References 218 publications

Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis

Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis

Terapia nebulizada. Año SEPAR

Alumina-Hydroxyapatite-Silver Spheres With Antibacterial Activity

Contact Info

Product

Resources

About